Stay updated with breaking news from Psytech Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Strategic investment in Beckley Psytech reinforces atai’s position as the biopharmaceutical company with the largest and most diverse portfolio of clinical-stage psychedelic candidatesTwo...
/PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative...
OXFORD, England--(BUSINESS WIRE)--Oct 24, 2023--
BPL-003 is Beckley Psytech's patent-protected benzoate formulation of 5-MeO-DMT (also known as Mebufotenin) and is administered intranasally via an FDA-approved delivery device. The multi-centre
Open-label study will investigate the safety, efficacy and pharmacokinetics of BPL-003 in patients diagnosed with alcohol use disorder (AUD). BPL-003 is Beckley Psytech's patent-protected